Silence Therapeutics plc Weighted Average Exercise Price Of Share Options Exercisable In Share-based Payment Arrangement2019

Silence Therapeutics plc (SLNCF) had Weighted Average Exercise Price Of Share Options Exercisable In Share-based Payment Arrangement2019 of 383.31 GBP/shares as of 2023-12-31, per its 20-F filed 2024-03-13.

Discontinued › Notes › Compensation Related Costs

ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019 · last filed 2024-03-13

2023-12-31: Weighted Average Exercise Price Of Share Options Exercisable In Share-based Payment Arrangement2019 383.31 GBP/shares.
2022-12-31: Weighted Average Exercise Price Of Share Options Exercisable In Share-based Payment Arrangement2019 1.10K GBP/shares.
2021-12-31: Weighted Average Exercise Price Of Share Options Exercisable In Share-based Payment Arrangement2019 263.45 GBP/shares.
2020-12-31: Weighted Average Exercise Price Of Share Options Exercisable In Share-based Payment Arrangement2019 151.33 GBP/shares; Weighted Average Exercise Price Of Share Options Exercisable In Share-based Payment Arrangement2019 as first filed 1.51 GBP/shares.

GBP/shares

Period end	Weighted Average Exercise Price Of Share Options Exercisable In Share-based Payment Arrangement2019	Weighted Average Exercise Price Of Share Options Exercisable In Share-based Payment Arrangement2019 as first filed
2023-12-31	383.31 GBP/shares 20-F · filed 2024-03-13
2022-12-31	1.10K GBP/shares 20-F · filed 2024-03-13
2021-12-31	263.45 GBP/shares 20-F · filed 2024-03-13
2020-12-31	151.33 GBP/shares 20-F · filed 2023-03-15	1.51 GBP/shares 20-F/A · filed 2021-04-29
2019-12-31	31.96 GBP/shares 20-F · filed 2022-03-17	0.32 GBP/shares 20-F/A · filed 2021-04-29
2018-12-31	0.82 GBP/shares 20-F/A · filed 2021-04-29

USD/shares

Period end	Weighted Average Exercise Price Of Share Options Exercisable In Share-based Payment Arrangement2019
2023-12-31	$14.34 20-F · filed 2024-03-13
2022-12-31	$13.24 20-F · filed 2024-03-13